GGrantIndex
← Leaderboards

Chad Rydel Heatwole

University Of Rochester

$3,337,588
Attributed
$3,337,588
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $506.1K · FY200824
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$3,337,588 · 4

By mechanism

R01$1,977,191 · 1
K23$647,755 · 1
U01$509,362 · 1
R34$203,280 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Muscular Dystrophies

Research focus

Muscular DystrophiesClinical TrialsAdultFacioscapulohumeral Muscular DystrophyClinical ResearchLaboratoriesResearch PersonnelIndexingLongitudinal StudiesAreaRegistriesInstitutesEvaluationInstrumentFundingResponseFunctional StatusFamily MemberFacility DesignsClinical SciencesEnvironmentInstrumentationAuthorityClinical Investigator

Grant awards (13)

STARFISH PIER: Study of Testosterone and rHGH in FSHD: Planning Infrastructure Execution and Readiness$203,280
R34 · FY2024 · AR · contact PI
STARFiSH: Study of Testosterone and rHGH in FSHD: A Proof-of-Concept Study$471,791
R01 · FY2020 · NS · contact PI
STARFiSH: Study of Testosterone and rHGH in FSHD: A Proof-of-Concept Study$506,051
R01 · FY2019 · NS · contact PI
STARFiSH: Study of Testosterone and rHGH in FSHD: A Proof-of-Concept Study$501,120
R01 · FY2018 · NS · contact PI
STARFiSH: Study of Testosterone and rHGH in FSHD: A Proof-of-Concept Study$498,229
R01 · FY2017 · NS · contact PI
Development of a Clinically Relevant Outcome Measure for FSHD Therapeutic Trials$132,210
U01 · FY2015 · AR · contact PI
Development of a Clinically Relevant Outcome Measure for FSHD Therapeutic Trials$196,331
U01 · FY2014 · AR · contact PI
Development of a Clinically Relevant Outcome Measure for FSHD Therapeutic Trials$180,821
U01 · FY2013 · AR · contact PI
The Development and Use of a Disease-Specific Instrument for Myotonic Dystophy$129,551
K23 · FY2012 · AR · contact PI
The Development and Use of a Disease-Specific Instrument for Myotonic Dystophy$129,551
K23 · FY2011 · AR · contact PI
The Development and Use of a Disease-Specific Instrument for Myotonic Dystophy$129,551
K23 · FY2010 · AR · contact PI
The Development and Use of a Disease-Specific Instrument for Myotonic Dystophy$129,551
K23 · FY2009 · AR · contact PI
The Development and Use of a Disease-Specific Instrument for Myotonic Dystophy$129,551
K23 · FY2008 · AR · contact PI